Literature DB >> 14605812

Prognostic significance of Ki-67 expression for patients with laryngeal squamous cell carcinoma primarily treated by total laryngectomy.

Mustafa Fuat Acikalin1, Ulkü Oner, Nilüfer Tel, Ozgül Paşaoğlu, Hamdi Cakli, Ertuğrul Colak.   

Abstract

The aim of this study was to determine the prognostic value of Ki-67 immunostaining in laryngeal squamous cell carcinomas. Ki-67 labeling was quantified in 63 laryngeal squamous cell carcinomas by counting at least 1,000 tumor cells in the most immunoreactive area in each sample, and the Ki-67 labeling index was calculated as a percentage. The antigen expression was compared with clinical factors, histopathological grading and prognosis. The Ki-67 mean proliferation index for all patients was 25.44% ( range, 2-75%). A significant correlation was found between Ki-67 mean proliferation index and patient age ( P<0.05), T-stage ( P<0.05), nodal metastasis ( P=0.001) and recurrence ( P<0.001). There was no significant association between the Ki-67 mean proliferation index and tumor site or histologic grade. A univariate analysis showed that the Ki-67 labeling index >21% ( P<0.001), T-stage ( P<0.001) and nodal metastasis ( P=0.001) are determinants of recurrence. In the multivariate analysis, the Ki-67 labeling index >21% ( P<0.001), T-stage ( P<0.001) and nodal metastasis ( P<0.05) were independent predictors of recurrence. Kaplan-Meier plots of survival in patients with Ki-67 values above and below the median (21%) of the general study population showed that a high Ki-67 labeling index correlated with a shorter disease-free survival ( P<0.0001). The analysis of the Ki-67 labeling index at the time of initial surgery may be a powerful prognostic marker for patients with laryngeal squamous cell carcinoma and may be useful for selecting subgroups of patients who should be treated with more aggressive therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605812     DOI: 10.1007/s00405-003-0699-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  18 in total

1.  Immunogold labelling of PCNA and Ki-67 antigen at the ultrastructural level in laryngeal squamous cell carcinoma and its correlation with lymph node metastasis and histological grade.

Authors:  A Grzanka; R Sujkowska; A Janiak; M Adamska
Journal:  Acta Histochem       Date:  2000-05       Impact factor: 2.479

2.  The relationship between survival and cell proliferation index in squamous cell carcinoma of larynx.

Authors:  A Pérez Carro Ríos; T García Caballero; A Lozano Ramírez; M D Arias Santos; A Soto Varela; J Forteza Vila; T Labella Caballero
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  2000

3.  Syndecan-1: a new prognostic marker in laryngeal cancer.

Authors:  J O Pulkkinen; M Penttinen; M Jalkanen; P Klemi; R Grénman
Journal:  Acta Otolaryngol       Date:  1997-03       Impact factor: 1.494

4.  Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus.

Authors:  E M Youssef; T Matsuda; N Takada; H Osugi; M Higashino; H Kinoshita; T Watanabe; Y Katsura; H Wanibuchi; S Fukushima
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

5.  Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.

Authors:  H Holte; C de Lange Davies; K Beiske; T Stokke; P F Marton; E B Smeland; J Høie; S Kvaløy
Journal:  Int J Cancer       Date:  1989-12-15       Impact factor: 7.396

6.  Prognostic factors in laryngeal carcinoma. Experience in 296 male patients.

Authors:  R Pradier; A González; E Matos; D Loria; R Adan; P Saco; L Califano
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

7.  Langerhans cells related to prognosis in patients with laryngeal carcinoma.

Authors:  O Gallo; G A Libonati; E Gallina; O Fini-Storchi; A Giannini; C Urso; R Bondi
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1991-09

8.  Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases.

Authors:  E Pera; A Moreno; L Galindo
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

9.  Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma.

Authors:  M F Spafford; J Koeppe; Z Pan; P G Archer; A D Meyers; W A Franklin
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-06

10.  Ki-67 labeling index is a more reliable measure of solid tumor proliferative activity than tritiated thymidine labeling.

Authors:  P Deshmukh; L Ramsey; H S Garewal
Journal:  Am J Clin Pathol       Date:  1990-08       Impact factor: 2.493

View more
  5 in total

Review 1.  The clinical relevance of Ki-67 expression in laryngeal squamous cell carcinoma.

Authors:  Federico Maria Gioacchini; Matteo Alicandri-Ciufelli; Giuseppe Magliulo; Corrado Rubini; Livio Presutti; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-03       Impact factor: 2.503

2.  A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions.

Authors:  Jack Y Yang; Mary Qu Yang; Zuojie Luo; Yan Ma; Jianling Li; Youping Deng; Xudong Huang
Journal:  BMC Genomics       Date:  2008       Impact factor: 3.969

3.  A study on the relationship between clinical features with Ki67 expression and eosinophil cells infiltration in oral squamous cell carcinoma.

Authors:  Noushin Jalayer Naderi; Farrokh Tirgari; Mohammad Javad KharaziFard; Fateme Farahani Parsa
Journal:  Med J Islam Repub Iran       Date:  2014-10-20

4.  Immunohistochemical Evaluation of Angiogenesis and Cell Proliferation in Tongue Squamous Cell Carcinoma.

Authors:  Maryam Khalili; Nazanin Mahdavi; Razieh Beheshti; Fereshteh Baghai Naini
Journal:  J Dent (Tehran)       Date:  2015-11

5.  The expression and significance of AKR1B10 in laryngeal squamous cell carcinoma.

Authors:  Jixuan Liu; Hongyan Ban; Yafang Liu; Jinsong Ni
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.